Shots:

• The P-I clinical trial involves assessing CT-P59 (20/40/80 mg/kg) vs PBO in 18 patients with mild symptoms of SARS-COV-2 infection who were randomized into 3 cohorts
• Results: patients demonstrated a 44% reduction in mean clinical recovery time- while no patients required hospitalization or antiviral therapy
• Celltrion has submitted the IND application for the clinical trial globally & plans to conduct global P-II & P-III trials including Korea. Additionally- Celltrion has also initiated a post-exposure prophylaxis study assessing CT-P59 as a protective treatment- by investigating the efficacy of the treatment in those who have been in contact with confirmed SARS-CoV-2 infected patients

 ­ Ref: Businesswire | Image: Celltrion